Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, announced new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The data demonstrate that the company's next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein to wild-type levels in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, Tevard presented findings showing durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The implications of these results are significant for patients with genetic diseases caused by nonsense mutations, which result in premature stop codons and truncated, nonfunctional proteins. Tevard's suppressor tRNA platform is designed to read through these premature termination codons, allowing the cellular machinery to produce full-length, functional proteins. According to the company, the sup-tRNAs achieved approximately 100% restoration of full-length dystrophin in DMD models, a critical step toward a potential therapy for this devastating muscle-wasting disease. DMD affects approximately 1 in 3,500 male births worldwide, and current treatments primarily address symptoms rather than the underlying genetic cause.
For DCM-TTNtv, a leading genetic cause of dilated cardiomyopathy, Tevard's sup-tRNAs demonstrated durable rescue of full-length titin, a giant protein essential for heart muscle structure and function. The data included functional rescue in human cardiomyocyte models, suggesting the therapy could restore normal heart cell contraction. This is particularly important because DCM often leads to heart failure and is a major indication for heart transplantation.
Tevard's compact tRNA architecture enables flexible packaging into adeno-associated virus (AAV) vectors, allowing precise dose control and broad applicability for diverse pathogenic nonsense mutations. This versatility means the platform could be adapted for many genetic diseases beyond DMD and DCM, including neurological disorders. The company is advancing programs in muscular dystrophies, heart disease, and neurological conditions, aiming to address high unmet medical needs.
The presented data underscore the potential of suppressor tRNA therapy to restore native protein expression in a cell-specific, durable manner. Unlike gene replacement or editing approaches, sup-tRNAs do not permanently alter the genome, offering a potentially safer alternative. Tevard's next-generation sup-tRNAs appear to overcome previous limitations of read-through therapies, such as toxicity or incomplete rescue.
For more information, visit Tevard Biosciences.
